Through cytokine screening, we identified that interleukin-1β ... was normalized to GAPDH as relative unit (RU). Gene-deficient THP-1 or HEK293T cells were generated using CRISPR/Cas9-mediated gene ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

here's why it might be worth investing in these drugmakers. CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle cell disease (SCD) and transfusion ...

CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Editas and CRISPR are probably most closely ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

the medicine should generate well over $1 billion in sales at its peak. Second, CRISPR has several other promising pipeline candidates. Recently, the U.S. Food and Drug Administration (FDA ...